1. Eriksson, Anna M, Emini, Nora, Harbo, Hanne F, Berge, Tone. 2025. Is DEXI a Multiple Sclerosis Susceptibility Gene? In International journal of molecular sciences, 26, . doi:10.3390/ijms26031175. https://pubmed.ncbi.nlm.nih.gov/39940946/
2. Dos Santos, Reinaldo S, Marroqui, Laura, Velayos, Teresa, Castaño, Luis, Santin, Izortze. 2018. DEXI, a candidate gene for type 1 diabetes, modulates rat and human pancreatic beta cell inflammation via regulation of the type I IFN/STAT signalling pathway. In Diabetologia, 62, 459-472. doi:10.1007/s00125-018-4782-0. https://pubmed.ncbi.nlm.nih.gov/30478640/
3. Nieves-Bonilla, Janice M, Kiaf, Badr, Schuster, Cornelia, Kissler, Stephan. 2019. The type 1 diabetes candidate gene Dexi does not affect disease risk in the nonobese diabetic mouse model. In Genes and immunity, 21, 71-77. doi:10.1038/s41435-019-0083-y. https://pubmed.ncbi.nlm.nih.gov/31435002/
4. Su, Chenhe, Lu, Fang, Soldan, Samantha S, Kossenkov, Andrew V, Lieberman, Paul M. 2021. EBNA2 driven enhancer switching at the CIITA-DEXI locus suppresses HLA class II gene expression during EBV infection of B-lymphocytes. In PLoS pathogens, 17, e1009834. doi:10.1371/journal.ppat.1009834. https://pubmed.ncbi.nlm.nih.gov/34352044/
5. Li, Wenqing, Wang, Zihao, Jiang, Ziming, Wang, Ming, Qin, Zhihai. 2023. MiR-3960 inhibits bladder cancer progression via targeting of DEXI. In Biochemical and biophysical research communications, 668, 8-18. doi:10.1016/j.bbrc.2023.05.055. https://pubmed.ncbi.nlm.nih.gov/37230046/
6. Miyaki, Yuichiro, Suzuki, Koichi, Koizumi, Kei, Shiya, Norihiko, Konishi, Fumio. 2011. Identification of a potent epigenetic biomarker for resistance to camptothecin and poor outcome to irinotecan-based chemotherapy in colon cancer. In International journal of oncology, 40, 217-26. doi:10.3892/ijo.2011.1189. https://pubmed.ncbi.nlm.nih.gov/21901246/
智鼠故事 
